Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats

American Journal of Hypertension

Volumn 17, Issue 9, 2004, Pages 749-756

  Wu, Lingyun ^a,b   Wang, Rui ^a   De Champlain, Jacques ^c   Wilson, Thomas W ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

hypertension; peroxisome proliferator activated receptor (PPAR); PPAR; Rosiglitazone; ventricular hypertrophy

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFECT; EXPERIMENTAL RAT; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; SPONTANEOUSLY HYPERTENSIVE RAT; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; VASCULAR TISSUE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY; MALE; MYOCARDIUM; ORGAN SIZE; PEROXISOME PROLIFERATORS; PPAR ALPHA; PPAR GAMMA; PYRIMIDINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TACHYCARDIA; THIAZOLIDINEDIONES; WEIGHT GAIN;

EID: 4444358440     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2004.04.010     Document Type: Article

References (30)

1. I. Issemann, S. Green Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 347 1990 645 650
2. C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, W. Wahli Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors Cell 68 1992 879 887
3. L. Fajas, D. Auboeuf, E. Raspe, K. Schoonjans, A.M. Lefebvre, R. Saladin, J. Najib, M. Laville, J.C. Fruchart, S. Deeb, A. Vidal-Puig, J. Flier, M.R. Briggs, B. Staels, H. Vidal, J. Auwerx The organization, promoter analysis, and expression of the human PPARgamma gene J Biol Chem 272 1997 18779 18789
4. R. Mukherjee, L. Jow, G.E. Croston, J.R. Paterniti Jr Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists J Biol Chem 272 1997 8071 8076
5. T.M. Willson, P.J. Brown, D.D. Sternbach, B.R. Henke The PPARs from orphan receptors to drug discovery J Med Chem 43 2000 527 550
6. R.E. Law, S. Goetze, X.P. Xi, S. Jackson, Y. Kawano, L. Demer, M.C. Fishbein, W.P. Meehan, W.A. Hsueh Expression and function of PPARgamma in rat and human vascular smooth muscle cells Circulation 101 2000 1311 1318
7. I. Barroso, M. Gurnell, V.E. Crowley, M. Agostini, J.W. Schwabe, M.A. Soos, G.L. Maslen, T.D. Williams, H. Lewis, A.J. Schafer, V.K. Chatterjee, S. ORahilly Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension Nature 402 1999 880 883
8. K. Rett The relation between insulin resistance and cardiovascular complications of the insulin resistance syndrome Diabetes Obes Metab 1 Suppl 1 1999 S8 S16
9. R.A. DeFronzo Insulin resistance a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis Neth J Med 50 1997 191 197
10. R.A. DeFronzo Insulin resistance, hyperinsulinemia, and coronary artery disease a complex metabolic web J Cardiovasc Pharmacol 20 Suppl 11 1992 S1 S16
11. T. Ogihara, H. Rakugi, H. Ikegami, H. Mikami, K. Masuo Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives Am J Hypertens 8 1995 316 320
12. B.H. Sung, J.L. Izzo Jr, P. Dandona, M.F. Wilson Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus Hypertension 34 1999 83 88
13. J.J. Nolan, B. Ludvik, P. Beerdsen, M. Joyce, J. Olefsky Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone N Engl J Med 331 1994 1188 1193
14. C.J. Tack, M.K. Ong, J.A. Lutterman, P. Smits Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone Diabetologia 41 1998 569 576
15. S. Yoshioka, H. Nishino, T. Shiraki, K. Ikeda, H. Koike, A. Okuno, M. Wada, T. Fujiwara, H. Horikoshi Antihypertensive effects of CS-045 treatment in obese Zucker rats Metabolism 42 1993 75 80
16. J.W. Grinsell, C.K. Lardinois, A. Swislocki, R. Gonzalez, J.S. Sare, J.R. Michaels, G.H. Starich Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat Am J Hypertens 13 2000 370 375
17. S. Verma, S. Bhanot, E. Arikawa, L. Yao, J.H. McNeill Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats Pharmacology 56 1998 7 16
18. Q.N. Diep, E.L. Schiffrin Increased expression of peroxisome proliferator-activated receptor-alpha and -gamma in blood vessels of spontaneously hypertensive rats Hypertension 38 2001 249 254
19. Q.N. Diep, M. El Mabrouk, J.S. Cohn, D. Endemann, F. Amiri, A. Virdis, M.F. Neves, E.L. Schiffrin Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats role of peroxisome proliferator-activated receptor-gamma Circulation 105 2002 2296 2302
20. L. Wu, B.H. Juurlink Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells Hypertension 39 2002 809 814
21. A.J. Scheen, P.J. Lefebvre Troglitazone antihyperglycemic activity and potential role in the treatment of type 2 diabetes Diabetes Care 22 1999 1568 1577
22. K. Saku, B. Zhang, T. Ohta, K. Arakawa Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits Am J Hypertens 10 1997 1027 1033
23. J.W. Kemnitz, D.F. Elson, E.B. Roecker, S.T. Baum, R.N. Bergman, M.D. Meglasson Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys Diabetes 43 1994 204 211
24. A.B. Walker, P.D. Chattington, R.E. Buckingham, G. Williams The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats Diabetes 48 1999 1448 1453
25. F.M. Martens, F.L. Visseren, J. Lemay, E.J. de Koning, T.J. Rabelink Metabolic and additional vascular effects of thiazolidinediones Drugs 62 2002 1463 1480
26. L. Wu, E. Eftekharpour, G.F. Davies, W.J. Roesler, B.H. Juurlink Troglitazone selectively inhibits glyoxalase I gene expression Diabetologia 44 2001 2004 2012
27. H.E. Lebovitz, M. Kreider, M.I. Freed Evaluation of liver function in type 2 diabetic patients during clinical trials evidence that rosiglitazone does not cause hepatic dysfunction Diabetes Care 25 2002 815 821
28. M. Higa, Y.T. Zhou, M. Ravazzola, D. Baetens, L. Orci, R.H. Unger Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats Proc Natl Acad Sci USA 96 1999 11513 11518
29. C.D. Toseland, S. Campbell, I. Francis, P.J. Bugelski, N. Mehdi Comparison of adipose tissue changes following administration of rosiglitazone in the dog and rat Diabetes Obes Metab 3 2001 163 170
30. A. Kermani, A. Garg Thiazolidinedione-associated congestive heart failure and pulmonary edema Mayo Clin Proc 78 2003 1088 1091